NCT04166383View on ClinicalTrials.gov

VB-111 in Combination With Nivolumab in People With Metastatic Colorectal Cancer (mCRC)

PHASE2CompletedINTERVENTIONAL
Enrollment

14

Participants

Timeline

Start Date

August 9, 2020

Primary Completion Date

April 12, 2022

Study Completion Date

December 31, 2022

Conditions
Metastatic Colorectal CancerColorectal NeoplasmsColorectal CarcinomaColorectal Cancer With Hepatic MetastasesColorectal Tumors
Interventions
BIOLOGICAL

Vascular Biogenics (VB)-111

1E13 or 0.7E13 VP via intravenous (IV) infusion on Day 1 of cycle 1 and continue every 6 weeks

DRUG

Nivolumab

240 mg of nivolumab via intravenous (IV) infusion on Day 1 of each cycle starting on cycle 2 and continue every 2 weeks

Trial Locations (1)

20892

National Institutes of Health Clinical Center, Bethesda

All Listed Sponsors
lead

National Cancer Institute (NCI)

NIH

NCT04166383 - VB-111 in Combination With Nivolumab in People With Metastatic Colorectal Cancer (mCRC) | Biotech Hunter | Biotech Hunter